Marijuana Sector News

0 16285

Today is the final trading day of the year will definitely be one that investors will always remember. The market remains in the positive as companies are better positioned for success. From the advance of the Canadian marijuana industry to election of Donald Trump, there will be a lot for investors to watch next year. We would like to highlight some themes anticipated to play out over 2017.


One of the brightest spots of the marijuana industry in 2016 was the Canadian licensed medical marijuana producer sub-sector. In early December, Mettrum Health (MT.V)(MQTRF) and Canopy Growth (CGC.TO)(TWMJF) announced an agreement where Canopy Growth will gain all of the outstanding shares of Mettrum.

Keep your eyes on the marijuana industry as it is expected to see more deals like this over the next year. The possibility for increase consolidation makes these companies attractive investment opportunities: Aphiria (APH.V)(APHQF), Supreme (SL.V)(SPRWF), OrganiGram (OGI.V)(ORGMF), Emblem Corporation (EMC.V), and Aurora Cannabis (ACB.V)(ACBFF).


The biotech sector will be one of the greatest recipients of the legal marijuana movement and recent sector weakness has created opportunities for investors.
GW Pharmaceuticals (GWPH) reported its second Stage Three Clinical trial in September for its Epidiolex product for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We continue to view GWPH as one of the top marijuana investments due to its capability to convert the cannabis industry through the development of treatments for sickness’ that don’t currently have an approved regimen.


From the financial structure, investors need to conduct with earnestness. We suggest incorporating some guidelines into your investment blueprint.

To end 2016, we want to highlight some of the stocks investors should watch during next year: Emblem Corporation (EMC.V)(EMMBF), Zoned Properties (ZDPY), Aphria (APHQF), Kush Bottles (KSHB), American Cannabis (AMMJ), Aurora (ACBFF), Reliq Healthcare (RQHTF), Zynerba Pharmaceuticals (ZYNE), OrganiGram (OG.V)(ORGMF), Arcturus Grothstar Tech (AGSTF), MassRoots (MSRT), VPR Brands (VPRB), CV Sciences (CVSI), mCig (MCIG), Canopy Growth (TWMJF)(CGC.TO), Medicine Man Tech (MDCL), GW Pharmaceuticals (GWPH), Lexaria (LXRP), Canabo Medical (CMM.V)(CAMDF), Mettrum Health (MT.V), and VinergyRes (VIN.CN).

We receive roughly 50-100 emails per day, 7 days per week 365 days per year asking the following;

How do I get started trading stocks specifically Marijuana Stocks?

In order to buy any kind of stock you need a brokerage account. You need to know how to fund that account and eventually how to properly place buy and sell orders and last but not lease how to read and understand level 2. We found a series of short videos on YouTube that we posted on our page that will help you get up and trading quickly so you can take advantage of the HOT Marijuana Stocks.

Learn how to get started trading stocks right here right now

What Marijuana Stocks are worth Buying?

We cover all publicly traded marijuana stocks on our website. From time to time we identify those that stand apart from the crowd, the cream of the crop. When we identify these companies, we begin taking steps to alert them to YOU our audience.

Speaking of MJ Stocks Worth Buying…

We believe investors need to focus their attention on the cannabis biotech sector RIGHT NOW. Recent political shifts are setting up a “perfect storm” scenario for the cannabis biotech sector. One biotech fund manager even said he thinks the entire sector is about to double. For this reason, we will be profiling a new cannabis biotech company that we will be sticking with long term. PLEASE read that AGAIN, we said LONG TERM. In other words, this will NOT be a “Day Trade.” Not a “quick flip”. For those that don’t know Biotech & Marijuana are two of the HOTTEST sectors right now and will ONLY continue to get BIGGER and BIGGER as technology & law/ regulations advances.

Before We Alert this New, Company You Need to do 2 Things;

Again, PLEASE read, Why Cannabis Biotech Needs to be in Your Portfolio Right Now Here

7 5296

The biotech sector may be one of the biggest beneficiaries of the legal cannabis movement.

In previous articles, we have been quite vocal about our bullish stance on the cannabis biotech sector. In the current US markets, we believe the greatest opportunity lies in biotech and the pharmaceutical production of cannabinoid and cannabis related drug treatments. And recent political shifts may have just created a perfect storm for cannabis biotech investors. Right now could be your greatest opportunity to consider adding cannabis biotech to your portfolio. And we aren’t the only ones who think so.

Todd Hagopian, manager of a biotech fund at Marketocracy, believes the biotech sector will benefit most from a Donald Trump Presidency. Todd is one of the most successful biotech investors in the market today. His returns have averaged 26.03% since starting his fund in 2011, which compares nicely to the S&P 500’s 11.58% return over the same period. Over the last five and three year periods, Todd Hagopian did better than the top U.S. Equity fund managers.

But why are we so bullish on cannabis biotech?

For over a year, analysts have been anticipating and factoring in a Hillary Clinton victory that sent the ishares NASDAQ Biotechnology ETF (IBB) plummeting 23% from 9/21/15 through Election Day this November. Why? Clinton was very vocal about her desire to slash what she believed to be excessive profits in the biotech industry. This would force drug companies to lower prices that would tighten margins and decrease net profit. If Clinton won the election, there were concerns that she would flip the Senate and/or House of Representatives to Democratic control. This would have allowed her to take action on the pricing practices of the biotech sector.

But with the White House and Congress now in Republican control, the biotech sector is set up for an extraordinary comeback. In fact, it has already begun. The IBB is up about 10% since Election Day. With Trump taking the White House, biotech investors could be in for one heck of a ride as this could be just the beginning of a move that could see the biotech sector double.

In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%.  This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

This is the perfect storm for cannabis biotech investors. Not only is the overall biotech industry expected to experience a massive bull run, but cannabis legalization is quickly spreading across the US. The November Election Day was an enormous victory for the cannabis industry. There are now 8 states that allow the recreational use of marijuana and another 21 that allow its medical use. We could be looking at a golden opportunity for cannabis biotech investors.

In his interview with Forbes, Hagopian went on to name a few other catalysts that biotech investors seem to have in their favor:

  1. The Obamacare fight needs to stay away from pricing. The odds of a Republican House and Senate trying to pass a law regulating drug prices, and have it signed by a Republican President seems slim to none.
  2. The Supreme Court needs to stay conservative. Donald Trump has already promised to nominate conservative judges to the court. The Supreme Court will likely stay 5-4, or even 6-3, in favor of conservative views.
  3. M&A activity needs to restart. The low valuations seen in the biotech sector after the Clinton selloff mentioned earlier in this article has sparked a ton of M&A rumors in the biotech sector. The Clinton biotech scare not only provided great opportunity for individual investors but also for large biotech titans to swallow up smaller companies with promising intellectual property and clinical data from early drug trials. We have already seen recent M&A activity in the cannabis sector with Canopy Growth Corp., Canada’s largest marijuana company, agreeing to buy competitor Mettrum Health Corp. for $8.42 a share.

The current environments of the overall biotech sector and marijuana industry have created an exciting time for cannabis biotech investors. Several catalysts are aligning for what could be a booming 2017 for the entire space. In addition, many companies are expected to announce FDA clinical and pre-clinical trial data soon. Favorable results will be a catalyst to send individual stocks and the overall cannabis biotech sector considerably higher.

If you haven’t done so already, it’s time to consider adding cannabis biotech to your portfolio, Now!

0 3109

Terra Tech Subsidiary Edible Garden to Participate in The New York Produce Show and Conference December 7th

Edible Garden will have an exhibit booth at the show displaying both new and existing products including its SUPERLEAF™ product and organic herbs. Following the Produce Show, Edible Garden will be rolling out its Living SUPERLEAF™ Spring Mix and Cut SUPERLEAF™ Spring Mix to existing Northeast supermarket customers.

Derek Peterson, Chairman and CEO of Terra Tech commented, “The New York Produce Show and Conference offers Edible Garden a prime opportunity to display and market the beneficial and nutritional properties of our organic SUPERLEAF™ lettuce to such a prospective audience. Our non-GMO verified SUPERLEAF™ lettuce continues to be a popular item for customers looking for enhanced nutritional benefits as one serving of this lettuce contains more than twice the amount of antioxidants as blueberries. The rollout of SUPERLEAF™ to existing customers in the Northeast will only expand our footprint as we aim to gain market share for Edible Garden and drive shareholder value.”

To be added to the Terra Tech email distribution list, please email with TRTC in the subject line.

About Terra Tech

Terra Tech Corp. (TRTC) operates through multiple subsidiary businesses including: Blüm, IVXX Inc., Edible Gardens, MediFarm LLC and GrowOp Technology. Blüm’s retail medical cannabis facilities focus on providing the highest quality medical cannabis to patients who are looking for alternative treatments for their chronic medical conditions. Blüm offers a broad selection of medical cannabis products including; flowers, concentrates and edibles through its Oakland, CA and multiple Nevada locations. IVXX, Inc. is a wholly-owned subsidiary of Terra Tech that produces medical cannabis-extracted products for regulated medical cannabis dispensaries throughout California. The Company’s wholly-owned subsidiary, Edible Garden, cultivates a premier brand of local and sustainably grown hydroponic produce, sold through major grocery stores such as ShopRite, Walmart, Winn-Dixie, Raley’s, Meijer, Kroger, and others throughout New Jersey, New York, Delaware, Maryland, Connecticut, Pennsylvania and the Midwest. Terra Tech’s MediFarm LLC subsidiaries are focused on medical cannabis cultivation and permitting businesses throughout Nevada. The Company’s wholly-owned subsidiary GrowOp Technology specializes in controlled environment agricultural technologies.

For more information about Terra Tech Corp visit:
For more information about IVXX visit:
For more information about Blüm Nevada visit:
For more information about Blüm Oakland visit:
Visit us on Facebook @
Follow us on Twitter @terratechcorp
Follow us on Instagram @socal_IVXX
For more information about Edible Garden visit:
Visit Edible Garden on Facebook @
Visit IVXX on Facebook @

About The New York Produce Show and Conference

The four-day event, presented by PRODUCE BUSINESS magazine and the Eastern Produce Council, includes networking opportunities, a trade show of over 400 companies, retail “Thought-Leader” breakfast panel hosted by Perishable Pundit Jim Prevor, educational micro-sessions, ag and culinary student outreach and tours of the region’s vibrant industry, including the local retailers, wholesalers, foodservice distributors, urban farms and unique eateries.

1 3184

American Green Integrates World Class Biometrics in the American Green Machine

American Green, Inc. ( OTC PINK : ERBB ) is pleased to announce that it has selected M2SYS (, the premier company in biometric technology, to complete its systems integration with the American Green Machine, or ‘AGM.’ M2SYS provides technology to many government organizations internationally. Initially M2SYS will provide the M2-FingerVein™, a non-invasive finger vein reader for the ‘AGM.’ Cuts, dry skin, scars, and other factors can sometimes prevent fingerprint readers from reliably enrolling or identifying a person for smart vending use. The M2-FingerVein™ reader solves this by capturing images of the vein patterns inside a finger. Because these unique patterns are inside the body, finger vein patterns are virtually impossible to reverse engineer and replicate. American Green’s use of this specialized technology also solves the issue of low light instances where facial recognition can pose a challenge. Most of all, M2SYS is designed to scale and can support multi-regional verification which will be important as the American Green Machine gains footholds nationwide.

“It’s one thing to create a platform that’s exciting with a lot of ‘wow’ factor… and we have done that,” says David Gwyther, chairman and acting president of American Green. “It’s quite another thing to provide comfort to people, organizations, and regulators where they can be assured, to the maximum extent possible today, that the appropriate person is making a ‘regulated purchase.’ We feel that M2SYS is the ‘best in class’ for integration into our American Green Machine,” Gwyther concludes.

“We are pleased to work with American Green. They are clearly on the forefront of a rapidly emerging application of biometrics — auto-retail or ‘smart vending,’ says Michael Trader, President of M2SYS. “Their ideas relating to safe and secure purchase through machine vending represent a new era in commerce and we are glad to support them in their initiatives. Their appreciation and focus on correct matching for the safety and security of people using the AGM is one of the reasons M2SYS has worked so hard to produce the products we have — so we can securely support new and existing business initiatives as well as government and large-scale corporate applications,” finished Mr. Trader. For more information you can contact John Trader at, 410-491-5354.

The American Green Machines also known as ‘the Ultimate AGMs’ are scheduled to begin shipping by the end of year and feature a processor or ‘machine brain’ created by technology partner Silkron® ( and can be configured in myriad ways, according to client wishes, whether the client is selling coconut water, beer, cannabis, or any regulated or non-regulated product. See Silkron’s demonstration pages for examples of how smart vending is changing the world of smart vending:

Be sure to visit the company’s website at and sign up for the company’s emails alerts to stay current on news. The company has over 6,000 shareholders and interest-holders on its private list and the list is growing every month. In addition, shareholders can join in the conversation here:


Except for any historical information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission reports and filings. Certain statements contained in this release that are not historical facts constitute forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, and are intended to be covered by the safe harbors created by that Act. Reliance should not be placed on forward-looking statements because they involve unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied. Forward-looking statements may be identified by words such as estimates, anticipates, projects, plans, expects, intends, believes, should and similar expressions and by the context in which they are used. Such statements are based upon current expectations of the Company and speak only as of the date made. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which they are made.

0 1953

Hempco Food and Fibre Inc. to Utilize Lexaria’s Patented Technology

Lexaria Bioscience Corp. (LXRP) (CSE:LXX) (“the Company” or “Lexaria”) is pleased to announce the entry of a letter of intent (the “LOI”) for the licensing of its proprietary absorption and palatability enhancing technology to Hempco Food and Fiber Inc. (HEMP.V) (“Hempco®”).

Under the auspices of the LOI, Hempco® and Lexaria begin lab tests and formulations this week to evaluate proprietary methods of applying Lexaria’s newly-patented technology for Hempco’s needs and demands. Hempco’s® already-excellent award winning food products may be enhanced with Lexaria’s patented technology.

“The combination of Hempco’s existing product innovations and proprietary manufacturing methods combined with Lexaria’s patented food flavour-masking and nutrient delivery enhancement technology is hoped to create manufacturing and technology synergies powerful enough to create a quality gap that other hemp food providers and the world’s leading brands in the sector will find difficult to match,” said Hempco CEO, Charles Holmes. “In our efforts to make the finest and most innovative and healthy hemp seed foods possible, the Lexaria technology is a perfect fit for us, and an excellent addition to our award winning PLANETHEMP brand retail line of products.”

Hempco® and the Holmes family is a pioneer in hemp protein powders and an innovator in manufacturing and global distribution of hemp based foods with wide applications. Hempco® recently launched its PlanetHemp brand of hemp seed nut, hemp seed oil, and hemp seed protein powder snacks in Canada and the UK to approximately 800 stores in North America as well as Europe and Asia.

Hempco® is vertically integrated from field to consumer products, and has rapidly growing international sales and distribution which also offers additional opportunity for synergies with Lexaria’s existing hemp-oil based products.

“I could not be happier than to engage in this LOI with Hempco,” said Chris Bunka, CEO of Lexaria Bioscience Corp. “We immediately begin product formulation testing and evaluation, and will work with all types of hemp food products such as proteins, seeds, oils and derivatives thereof, as we determine the most advantageous methods of embedding superior technology into Hempco’s product mix.”

Financial terms of the LOI are not disclosed at this time and are still under negotiation, but have already been narrowed down to agreed-upon ranges. The LOI is expected to advance into a definitive agreement within 90 days but there is no assurance of this. Further details regarding the completion of the definitive agreement and formulation development and testing will be announced as information becomes available. Readers are cautioned that if a definitive agreement is completed with Hempco®, much of Lexaria’s financial compensation is dependent upon the marketplace success of the Hempco® products enhanced with Lexaria’s technology.

About Lexaria

Lexaria Bioscience Corp. is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. Lexaria’s technology enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria hopes to reduce other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health.

About Hempco

Hempco® and the Holmes family is a trusted and respected pioneer, innovator and provider of premier hemp seed foods for more than 15 years. Hempco® is recognized as a “company that cares” and guarantees that its customers, all over North America, Europe and Asia, are provided the finest hemp seed foods possible. The Hempco® mandate has grown to “whole crop utilization” and is investigating hemp fiber and hemp CBD nutraceuticals to create a “tri-crop” opportunity for farmers. Hempco® has grown its business significantly and is generating value and profits for shareholders.


Lexaria Bioscience Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

2 1758

With marijuana on pace to be legalized in the United States in the next five to ten years, the conversation regarding hemp has begun to stir up. Hemp and marijuana are commonly confused because they both come from the Cannabis Sativa species of plant.

Hemp and marijuana were both prescribed as illegal during the Prohibition Era but the Agricultural Act of 2014 known as the Farm Bill, allowed states to study hemp for research purposes and classified industrial hemp as having .3% THC compared to marijuana’s 10-30%. On July 4, a petition will be delivered to Congress urging them to pass the Industrial Hemp Farming Act of 2015/2016.

Hemp can be used to produce many things including textiles, cars, food, homes, and more according to Rob Jungmann who owns Jungmaven, a hemp-loving company. It is also good for environment unlike many other crops including cotton. Hemp puts Nitrogen back into the soil and takes less water while producing more plants per acre. Jungmann alludes to California’s drought as a great reason for hemp to be legalized in the state.

Thirty countries allow industrial hemp to be grown, China being its biggest producer and exporter. Unlike any other product, the U.S. requires farmers to get DEA approval before they sew the seeds.

Michael Lewis, the director of Growing Warriors, a project devoted to helping the country’s veterans find livelihoods in sustainable agriculture, spoke of his experience with the DEA in a short film titled Harvesting Liberty. In 2014, the DEA wanted to prevent and arrest Lewis and the other farmers but a Louisville judge sided with the farmers. Growing Warriors was the first group of private citizens to grow hemp on US soil in 70 years.

0 1660

Agritek Holdings, Inc. Announcing Florida Trumps Vote With Yes On Amendment 2 Becoming First Southern State To Legalize Medical Marijuana

Amendment 2 recognizes marijuana as a treatment for ten (10) specified conditions and diseases:

  • Cancer
  • Epilepsy
  • Glaucoma
  • HIV
  • AIDS
  • Post-traumatic stress disorder
  • Amyotrophic lateral sclerosis
  • Crohn’s disease
  • Parkinson’s disease
  • Multiple sclerosis

The passing of Amendment 2 also allows Florida state licensed physicians to recommend marijuana for patients with other debilitating medical conditions of the same kind or class as or comparable to those enumerated. The Florida amendment will take effect on January 3rd 2017, after which the Florida Department of Health has six months to issue regulations for patients, caregivers (who help patients obtain and use marijuana), and medical marijuana treatment centers (which produce and dispense the drug).

Home cultivation is not permitted, and the department is charged with setting presumptive possession limits for patients. The state is expected to start issuing identification cards to qualifying patients and caregivers within nine months, and if it fails to do so a doctor’s certification will authorize access to medical marijuana.

As in 2014, the top financial supporter of Amendment 2 was Orlando trial lawyer John Morgan, a major Democratic donor, while the top financial supporter the opposition campaign was casino magnate Sheldon Adelson, a major Republican donor and ardent pot prohibitionist who hopes to expand his business into Florida. But while opponents of medical marijuana spent almost as much as supporters in 2014, they were outspent almost 2 to 1 this year.

This year’s version has a narrower definition of “debilitating medical condition” and clarifies the requirement for obtaining consent from parents of patients younger than 18. A law that took effect at the beginning of last year allows the use of low-THC, noncombusted marijuana by Florida residents with cancer or “a physical medical condition that chronically products symptoms of seizures or severe and persistent muscle spasms.” Amendment 2 applies to a wider range of conditions, give patients access to high-THC marijuana, and lets them smoke it.

Florida is one of multiple states voting on medical cannabis this election season. Amendment 2, the Florida Medical Marijuana Legalization Initiative, would let licensed physicians prescribe medical marijuana.

“We remember 2014 very well and losing our vote then by a narrow margin of 3% being the first public company within the cannabis sector headquartered in south Florida. This is the first of many extraordinary steps in a positive direction for our sector in the state. We are not planning on getting involved as we have done in the past on land purchases, seeking licenses to grow or any large infrastructure plays. Our plan is simple and strategic with the strongest foothold having the most knowledge within the sector in Florida. We plan to essentially be in the pick and shovel business. We already have one of the foremost physicians in the industry on our advisory board Dr. Stephen Holt, to help build a coalition among doctors who will be able to distribute medical marijuana under the new law. We have contracts in place with the largest encapsulation company based in Florida to provide pills or capsules to those patients who qualify and would most likely not smoke. We have just negotiated our license to distribute infused lozenges and gum tablets which may be infused with THC or CBD under a proprietary process which would be the most preferred delivery system for children with epilepsy and the elderly”, stated B. Michael Friedman, CEO of Agritek Holdings Inc.

“Agritek Holdings’ experience, Florida roots, public status and established relationships with physicians, vendors and knowledge of the science of cannabis will truly make us a meaningful partner as Florida moves towards the legalization process,” further stated Friedman.

About Agritek Holdings, Inc.

Agritek Holdings, Inc., a pioneer within the medicinal marijuana space, provides innovative technology and agricultural solutions and seeks to be the leader in Compassionate Care Technology for the recreational cannabis industry. Agritek Holdings, Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act, nor does it intend to do so in the future.

0 1888

Agritek Holdings, Inc. Announces Appearance As Feature Company On Cannabis Investor Webcast

 Agritek Holdings, Inc. ( OTC PINK : AGTK ), a leader in compassionate care technology and agricultural solutions for the recreational cannabis industry, today announced that it will present online on the CANNAINVESTOR Webcast ( on Thursday, November 3, 2016 at 3:00 PM ET – 3:45 PM ET.

The CANNAINVESTOR Webcast will include presentations from both privately-held and publicly-traded cannabis companies and industry professionals. The Agritek Holdings, Inc. feature presentation will be a 30-minute broadcast by the Company’s CEO B. Michael Friedman which will cover recent news events and the Company’s roll out strategy for new states voting on recreational markets with a focus on Prop 64 in California. The CEO broadcast will be followed by 15-minutes of Q&A. The CANNAINVESTOR Webcast is an ideal forum and opportunity for its online audience to research potential investments in sector related companies without taking time-off from work, paying registration fees and incurring travel-related expenses.

Cannabis investors, analysts, executives, media, and consumers who would like to attend the free online webcast, please click on the link and visit the Registration Page. After you register you will receive a link via e-mail to access the webcast on presentation day. To view the recorded presentations please visit and search for Cannabis Investor Webcast three weeks after the live presentation.

“We are very pleased to have been invited to this unique broadcast forum and to be featured on the next cover of the digital magazine for Canna Investor. The use of interactive media to expand our reach to a live investor audience and being able to speak to investors directly truly allows individuals the opportunity to make informed decisions while deciding to invest in this exciting sector,” stated B. Michael Friedman, CEO of Agritek Holdings Inc.

About Agritek Holdings, Inc.
Agritek Holdings, Inc., ( a pioneer within the medicinal and recreational marijuana space, provides innovative technology and agricultural solutions and seeks to be the leader in Compassionate Care Technology for the recreational cannabis industry. Agritek Holdings, Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act, nor does it intend to do so in the future.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Agritek Holdings, Inc. to be materially different from the statements made herein.

0 1457

Form 8-K for SURNA INC.


Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.On October 31, 2016, Surna Inc. (the “Company”) began private negotiations with certain holders of certain 10% convertible promissory notes (the “Original Notes”) and warrants (the “Original Warrants” and together with the Original Notes, the “Original Securities”) with a view to amending and converting the Original Notes and amending the terms of the Original Warrants.

The Original Securities were issued as part of a unit (each unit consisted of 250,000 shares of Common Stock, an Original Warrant to purchase 50,000 shares of Common Stock and an Original Note in the principal amount of $50,000) to investors participating in the Company’s private placement financing that completed closings between October 31, 2014 and February 27, 2015. The Original Notes mature and become payable two years from issuance.

The Company is negotiating individually with each holder to: (i) amend the Original Note (each an “Amended Note”) to reduce the conversion price of the Original Note to an amount which is expected to be below the Company’s recent trading price per share and simultaneously cause the conversion of the outstanding amount under such Original Note into shares of Common Stock of the Company (“Conversion Shares”); and (ii) reduce the exercise price of the Original Warrant (each, an “Amended Warrant” and together with an Amended Note, the “Amendments”) to an amount which is expected to be above the Company’s recent trading price per share. In connection with the Amendments, the Company is also negotiating a restriction that would limit the number of Conversion Shares a holder may sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any of such shares issuable in connection with the Amendments without the prior written consent of the Company for a period of ninety (90) days after the date of definitive documents are entered into.

The purpose of these negotiations is to encourage the amendment and conversion of the Original Notes by significantly reducing the conversion price and significantly reducing the exercise price of the Original Warrants. The Company believes this will help it to avoid an event of default from occurring under the Original Notes, reduce the amount of indebtedness recorded on its financial statements and improve the Company’s ability to attract new investors in potential future financing transactions. The Company believes that the amendment of the Original Warrants will make it more likely that a holder will exercise their respective Amended Warrant if the Company’s trading price per share exceeds the revised exercise price reflected in the Amended Warrant, which will result in cash proceeds that will assist the Company’s growth plans.

The Company can provide no assurance that any owner of the Original Securities will agree to these amendments. The Company may make different arrangements with different investors. The Company may engage a broker-dealer or financial consultant to assist it in conducting and completing these negotiations.

Important Information

The information in this Current Report on Form 8-K (this “Current Report”) is for informational purposes only, and the proposed transactions described above shall not constitute an offer to buy, exchange or amend securities or constitute the solicitation of an offer to sell, exchange or amend any of the Company’s securities. The holders of the Original Securities previously represented to the Company that they were accredited investors (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”)) in connection with the transactions in which such holders acquired the Original Securities. The Company will not modify a holder’s Original Securities if the Company does not have a reasonable belief that such holder currently is an accredited investor. Additionally, the Company will not modify the Original Securities if the Company determines that a valid securities exemption is not available under the Securities Act. The disclosure contained herein does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, and is made only as permitted by Rule 135c under the Securities Act.

Forward Looking Statements

This Current Report includes “forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Examples of forward-looking statements include, but are not limited to: (a) projections of revenues, capital expenditures, growth, prospects, dividends, capital structure and other financial matters; (b) statements of plans and objectives of the Company or its management or the Company’s board of directors; (c) statements of future economic performance; (d) statements of assumptions underlying other statements and statements about the Company and its business relating to the future; and (e) any statements using such words as “anticipate”, “believe”, “estimate”, “could”, “should”, “would”, “seek”, “plan”, “expect”, “may”, “predict”, “project”, “intend”, “potential”, “continue”, or similar expressions. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: uncertainties as to the timing of the transactions; uncertainties as to how many holders will agree to the terms of a transaction; the possibility that various closing conditions for the transactions may not be satisfied or waived; and other risks and the other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission (the “SEC”) and the Company’s other SEC filings. Except as otherwise required by law, the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this Current Report. All forward-looking statements in this Current Report are qualified in their entirety by this cautionary statement.


Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact
Ad Placements